Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Clin Cancer Res. 2015 Dec 9;22(7):1572–1582. doi: 10.1158/1078-0432.CCR-15-1965

Figure 1. Ibrutinib alters the expression of inflammatory cytokines and chemokines in serum from patients with CLL.

Figure 1

A, The percent changes in the evaluated chemokines after eight weeks on ibrutinib treatment compared to pre-treatment levels. B, The percent changes in evaluated inflammatory cytokines after eight weeks on ibrutinib treatment compared to pre-treatment levels. In both panels, median with interquartile range is shown. See supplementary table for complete list of tested cytokines/chemokines and changes over time. Statistical analyses were by Wilcoxon matched-pairs signed rank test. Asterisks indicate degree of statistical significance compared to pre-treatment levels: * P < .05, ** P < .01, *** P < .001, and **** P < .0001.